IONS
Ionis Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
43.52
close · 2026-10-30
value
70
cheaper than peers70
quality
37
stronger fundamentals37
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -4.4% | 73 |
| earnings yield, 2 years ago | -5.9% | 73 |
| earnings yield, 1 year ago | -7.0% | 67 |
| cash flow yield, 2 years ago | -4.6% | 65 |
| cash flow yield, latest year | -4.5% | 65 |
| cash flow yield, 3 years ago | -4.1% | 64 |
| earnings yield, latest year | -5.5% | 62 |
| price to sales | 6.83× | 62 |
| cash flow yield, 1 year ago | -7.6% | 58 |
| price to book | 16.39× | 13 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 87.0% | 74 |
| operating margin | -47.7% | 62 |
| return on equity | -67.6% | 36 |
| debt to equity | 531.0% | 5 |
4 of 4 measures available
Facts
| market cap | $7B |
| free cash flow | -$807.8M |
| employees | 1,402 |
| first trade | 1991-05-17 |
| next earnings | not reported |
| fundamentals updated | 2026-07-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.38 | -3.04 | -2.56 | -1.90 |
| free cash flow | -$325.7M | -$551.3M | -$335.5M | -$294.5M |
| net income | -$381.4M | -$453.9M | -$366.3M | -$269.7M |
| revenue | $943.7M | $705.1M | $787.6M | $587.4M |
| unusual items | $108.0M | $104.1M | $87.1M | $167.6M |